Mizuho Medy Co Ltd
TSE:4595
Mizuho Medy Co Ltd
Income from Continuing Operations
Mizuho Medy Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mizuho Medy Co Ltd
TSE:4595
|
Income from Continuing Operations
¥3.8B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Terumo Corp
TSE:4543
|
Income from Continuing Operations
¥125.1B
|
CAGR 3-Years
11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
15%
|
|
|
Olympus Corp
TSE:7733
|
Income from Continuing Operations
¥95.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Sysmex Corp
TSE:6869
|
Income from Continuing Operations
¥57.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
|
Nihon Kohden Corp
TSE:6849
|
Income from Continuing Operations
¥17.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
JEOL Ltd
TSE:6951
|
Income from Continuing Operations
¥31.5B
|
CAGR 3-Years
53%
|
CAGR 5-Years
37%
|
CAGR 10-Years
23%
|
|
Mizuho Medy Co Ltd
Glance View
Mizuho Medy Co., Ltd. engages in the research, development, manufacture and distribution of in-vitro diagnostic products. The company is headquartered in Tosu-Shi, Saga-Ken and currently employs 173 full-time employees. The company went IPO on 2015-12-17. The firm mainly provides in-vitro diagnostic pharmaceuticals, including immune serum test drugs, biochemical test drugs, urine and feces test drugs, microbial test drugs, blood test drugs, pathological test drugs and others, in hospital and medical practitioner fields. In addition, the Company also provides over-the-counter (OTC) drugs to pharmacies and drug stores, and sells fruit tree virus test drugs to which they apply the technology of immune serology test to agricultural test centers.
See Also
What is Mizuho Medy Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
3.8B
JPY
Based on the financial report for Dec 31, 2024, Mizuho Medy Co Ltd's Income from Continuing Operations amounts to 3.8B JPY.
What is Mizuho Medy Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
34%
Over the last year, the Income from Continuing Operations growth was 0%. The average annual Income from Continuing Operations growth rates for Mizuho Medy Co Ltd have been -8% over the past three years , 34% over the past five years .
You don't have any saved screeners yet